Brief: Hyloris Says Enrolls First Patient In Phase 3 Clinical Trial For Proprietary Mouth Rinse To Control Incidences Of Bleeding Related To Dental Procedures

Hyloris Pharmaceuticals SA

14/02/2024 17:04

Feb 14 (Reuters) - Hyloris Pharmaceuticals Sa  HYL.BR :
    * HYLORIS ENROLLS FIRST PATIENT IN PHASE 3 CLINICAL TRIAL
FOR ITS
PROPRIETARY MOUTH RINSE TO CONTROL INCIDENCES OF BLEEDING
RELATED TO DENTAL PROCEDURES
    * SAYS STUDY RESULTS EXPECTED FIRST HALF OF 2025
    * HYLORIS WILL SEEK REGULATORY APPROVAL IN UNITED STATES
FIRST,
BEFORE EXPANDING TO OTHER TERRITORIES
    * HYLORIS EXPECTS TO LICENSE PRODUCT CANDIDATE TO A PARTNER
FOR
COMMERCIALIZATION IN U.S.

Source text for Eikon:  ID:nGNE6S22zr 
Further company coverage:  HYL.BR 

 ((Reuters.Briefs@thomsonreuters.com;))